Mark T. Iwicki Sells 15,168 Shares of KALA BIO, Inc. (NASDAQ:KALA) Stock

KALA BIO, Inc. (NASDAQ:KALA) CEO Mark T. Iwicki sold 15,168 shares of the company’s stock in a transaction on Wednesday, June 26th. The shares were sold at an average price of $4.75, for a total value of $72,048.00. Following the completion of the sale, the chief executive officer now owns 263,755 shares in the company, valued at $1,252,836.25. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.

KALA BIO Trading Up 9.9 %

Shares of NASDAQ KALA opened at $7.09 on Friday. The company’s 50 day simple moving average is $6.39 and its 200 day simple moving average is $7.02. The company has a debt-to-equity ratio of 4.92, a current ratio of 4.22 and a quick ratio of 4.22. KALA BIO, Inc. has a fifty-two week low of $4.21 and a fifty-two week high of $16.11. The firm has a market capitalization of $19.99 million, a P/E ratio of -0.47 and a beta of -1.97.

KALA BIO (NASDAQ:KALA) last announced its quarterly earnings data on Tuesday, May 14th. The company reported ($4.20) EPS for the quarter, missing analysts’ consensus estimates of ($2.89) by ($1.31). On average, analysts predict that KALA BIO, Inc. will post -14.49 EPS for the current year.

Wall Street Analyst Weigh In

Several equities research analysts have recently weighed in on KALA shares. Oppenheimer reaffirmed an “outperform” rating and issued a $15.00 target price on shares of KALA BIO in a report on Monday, April 1st. HC Wainwright decreased their price objective on shares of KALA BIO from $21.00 to $18.00 and set a “buy” rating on the stock in a research note on Friday, May 17th.

Institutional Trading of KALA BIO

An institutional investor recently raised its position in KALA BIO stock. Knights of Columbus Asset Advisors LLC raised its position in KALA BIO, Inc. (NASDAQ:KALA) by 100.0% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 4,834 shares of the company’s stock after purchasing an additional 2,417 shares during the period. Knights of Columbus Asset Advisors LLC owned approximately 0.18% of KALA BIO worth $34,000 as of its most recent filing with the SEC. 24.61% of the stock is currently owned by institutional investors.

KALA BIO Company Profile

KALA BIO, Inc, a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of innovative therapies for rare and severe eye diseases in the United States. The company's product candidates include KPI-012, which is in Phase 2b clinical trial for the treatment of persistent corneal epithelial defects.